ArticleCancer research2009
Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 79 citations in OpenAlex.
- In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.Nature medicine · 2014Trial
- Development of Advanced Imaging and Molecular Imaging for Barrett's Neoplasia.Diagnostics (Basel, Switzerland) · 2022Review
- Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.International journal of environmental research and public health · 2020Review
- Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer.International journal of cancer · 2016Article
- Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages.American journal of cancer research · 2016Article
- Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.International journal of cancer · 2014Article
- Article
- Article
- MR - eyes for cancer: looking within an impenetrable disease.NMR in biomedicine · 2013Review
- Imaging cell surface glycosylation in vivo using "double click" chemistry.Bioconjugate chemistry · 2013Article
- Non-invasive molecular imaging for preclinical cancer therapeutic development.British journal of pharmacology · 2013Review
- Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.International journal of cancer · 2013Article
- Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues.Clinical breast cancer · 2013Article
- Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis.Oncogene · 2013Article
- Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis.Theranostics · 2013Article
- Multifunctional nanoparticles for drug delivery and molecular imaging.Annual review of biomedical engineering · 2013Review
- Article
- Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging.Neoplasia (New York, N.Y.) · 2012Article
- Magnetic nanoparticles for cancer diagnosis and therapy.Pharmaceutical research · 2012Review
- Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus.Nature medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
With the emerging concept of individualized cancer therapy, it becomes crucial to develop methods for the noninvasive assessment of treatment outcome. With this in mind, we designed a novel approach for the comprehensive evaluation of response to chemotherapy with the established agent doxorubicin in a preclinical breast cancer model. This approach delivers information not only about change in tumor size but also about target antigen expression. Our strategy relies on a tumor-specific contrast agent (MN-EPPT) targeting the underglycosylated MUC-1 (uMUC-1) tumor antigen, found on more than 90% of breast cancers and predictive of chemotherapeutic response. MN-EPPT consists of superparamagnetic iron oxide nanoparticles (MN) for magnetic resonance imaging, modified with Cy5.5 dye (for near-IR fluorescence optical imaging), and conjugated to peptides (EPPT), specifically recognizing uMUC-1. In vivo, treatment of mice bearing orthotopic human breast carcinomas with doxorubicin led to a reduction in tumor mass and resulted in down-regulation of uMUC-1. The tumor-specific accumulation of MN-EPPT allowed the assessment of change in tumor volume by noninvasive imaging. Furthermore, in mice injected with MN-EPPT, tumor delta-T2 was significantly reduced after treatment with doxorubicin, indicating a lower accumulation of MN-EPPT and reflecting the reduced expression of uMUC-1. With these studies, we have shown the utility of magnetic resonance imaging for the multiparametric characterization of breast tumor response to chemotherapy. This approach has the potential of significantly advancing our ability to better direct the development of molecularly targeted individualized therapy protocols because it permits the monitoring of therapy on a molecular scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.